Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy ; volume:199 ; number:2 ; day:22 ; month:3 ; year:2023 ; pages:231-241 ; date:6.2023
Breast cancer research and treatment ; 199, Heft 2 (22.3.2023), 231-241, 6.2023
- Creator
-
Iwata, Hiroji
Yamamoto, Yutaka
Sakai, Takehiko
Hasegawa, Yoshie
Nakamura, Rikiya
Akabane, Hiromitsu
Ohtani, Shoichiro
Kashiwaba, Masahiro
Taira, Naruto
Toyama, Tatsuya
Fujisawa, Tomomi
Masuda, Norikazu
Shibahara, Yukiko
Sasano, Hironobu
Yamaguchi, Takuhiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-023-06874-7
- URN
-
urn:nbn:de:101:1-2023090713272943689240
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Iwata, Hiroji
- Yamamoto, Yutaka
- Sakai, Takehiko
- Hasegawa, Yoshie
- Nakamura, Rikiya
- Akabane, Hiromitsu
- Ohtani, Shoichiro
- Kashiwaba, Masahiro
- Taira, Naruto
- Toyama, Tatsuya
- Fujisawa, Tomomi
- Masuda, Norikazu
- Shibahara, Yukiko
- Sasano, Hironobu
- Yamaguchi, Takuhiro
- SpringerLink (Online service)
Other Objects (12)
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
Endocrine disrupting chemicals : interaction with estrogen receptors an in vitro assessment of endocrine activity potential
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
Endocrine disrupting chemicals : interaction with estrogen receptors an in vitro assessment of endocrine activity potential
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
Endocrine disrupting chemicals : interaction with estrogen receptors an in vitro assessment of endocrine activity potential
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer